Aperiomics CEO Dr. Crystal Icenhour to Pitch for Venture Capital in Vinetta Showcase September 26th in DC

By |2018-09-19T17:52:45+00:00September 11th, 2018|

Ashburn, VA – September 11, 2018 – Dr. Crystal Icenhour, CEO of Aperiomics and one of the fastest rising stars in American biotechnology, has been chosen to compete in the annual Vinetta Showcase in Washington, DC.  Vinetta is a high-impact pitch and panel series in which top female founders of successful startup companies compete for venture capital.

The event is Wednesday, September 26, 6:30 – 9:00 p.m. at the Booz Allen Hamilton Innovation Center, 901 15th Street NW, Washington, D.C. A judging panel will be comprised of three active investors and a company CEO. The event is open to press. The audience will include entrepreneurs, venture influencers, young professionals and service providers, all of whom see massive growth potential for investing in female founders.

Dr. Icenhour is an expert in infectious disease diagnostics, with more than 25 years of experience in medical research and biotech. She holds two patents, has authored numerous research articles and theses, and is a prolific speaker. She has served on review panels for the National Science Foundation, the EPA and NIH. She is also an adjunct assistant professor at Duke University Medical Center and has done postdoctoral research at the Mayo Clinic.

Aperiomics is the only company of its kind and scope in the world. Its proprietary technology can identify every bacteria, DNA virus, fungi and parasite – the causes of infections — in a single test. It does this using a method called “deep shotgun metagenomic sequencing” of the DNA from any sample (patient, environmental, etc.).
It helps doctors and their patients worldwide solve difficult medical cases, limit the use of antibiotics, and drastically cut trial-and-error testing. Last year Aperiomics was recognized as one of the D.C. region’s most innovative companies as a finalist in The Greater Washington Innovation Awards. The company was named “Life Sciences Innovator of the Year” in 2016.

About Aperiomics

Aperiomics is the only company identifying every bacteria, DNA virus, fungi and parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test via deep metagenomic shotgun sequencing of DNA from any sample, be it patient, environmental, or otherwise. The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough, only possible through Aperiomics, can be used to accurately identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about our successes in helping others. Aperiomics is supported by the National Science Foundation. It was named Life Sciences Innovator of the Year in 2016 and a finalist in the 2018 Greater Washington Innovation Awards. For more information, visit www.aperiomics.com or call (703) 229-0406.